Case Study: Boston Scientific improves pulmonary embolism safety insights with Truveta Data

Assessing the comparative safety of novel pulmonary embolism treatments

Boston Scientific needed real-world evidence on the comparative safety of two newer pulmonary embolism treatments, but post-approval device performance data is difficult to study because of fragmented records, missing device details, and limited comparative trial data. The company wanted insight into bleeding risk and outcomes for its EkoSonic Endovascular System (EKOS) versus a mechanical thrombectomy alternative.

Using Truveta Data, Boston Scientific worked with independent researchers to identify patients via Unique Device Identifiers and analyze outcomes across both a primary cohort and a contemporary cohort. Truveta’s normalized, linked EHR data enabled assessment of hemoglobin drops, transfusions, major bleeding, mortality, and readmissions; the study found FlowTriever was associated with significantly higher bleeding-related events than EKOS, including more transfusions, larger hemoglobin decreases, and higher rates of ISTH and BARC 3b major bleeding.

Boston Scientific